At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE:PFE) shares will maintain this sort of valuation when that occurs. With the spin-off of Zoetis (NYSE:ZTS), years of restructuring, and a reorganization that will create “innovative” and “value” cores, I have to think that Pfizer management has pulled every trick out of its bag aside from a full break-up of the company. What's more, while there are some worthwhile products in the pipeline, I think the company is looking at pretty sluggish long-term growth as those new products will struggle to offset the loss of exclusivity on other lucrative drugs.
Read more here:
http://www.investopedia.com/stock-analysis/073013/pfizer-looking-little-tired-pfe-abbv-celg-rhhby.aspx
Investopedia: Pfizer Looking A Little Tired
0 comments:
Post a Comment